|
|
Programme
Indicated times are in CEST timezone.
| Confirmed Plenary Speakers (to Date) |
| Short break |
|
| Wednesday June 2, 2021 |
| Session 1 |
| 16:00 | Opening & introduction |
Dr Jean-Yves ORTHOLAND (EDELRIS, Lyon, France)
Dr Allen ANNIS (AILERON THERAPEUTICS, Cambridge, United States) |
|
| 16:10 | Targeting RNA With Small Molecules Using Affinity-Selection Mass Spectrometry (KL01) |
Dr Elliott B. NICKBARG
(MERCK & CO., INC., Boston, United States) |
|
| 16:55 | Discovery of Bioactive Natural Products Using Affinity Selection-Mass Spectrometry (PL01) |
Prof. Richard VAN BREEMEN
(OREGON STATE UNIVERSITY, Corvallis, United States) |
| |
|
| 17:40 | Accelerating Drug Discovery with the Integration of Affinity Selection Mass Spectrometry (PL02) |
Dr Damian HOUDE
(RELAY THERAPEUTICS, Cambridge, United States) |
|
| 18:15 | Fishing from an Exclusive Pond Using AS-MS (PL03) |
Dr Didier ROCHE
(EDELRIS, Lyon, France) |
|
| 18:30 | Closing remarks Day 1 |
|
|
|
| Thursday June 3, 2021 |
| Session 2 |
| 16:00 | Opening remarks |
Dr Didier ROCHE
(EDELRIS, Lyon, France) |
|
| 16:05 | Adapting the AS-MS Technology to GPCR Ligand Discovery (PL04) |
Prof. Wenqing SHUI
(SHANGHAITECH UNIVERSITY, Shanghai, China) |
|
| 16:40 | Lessons Learned from Pfizer’s Experience in utilizing Affinity Selection by Mass Spectrometry for Hit Identification (PL05) |
Dr Matthew D. TROUTMAN
(PFIZER, Groton, United States) |
| |
|
| 17:25 | MALDI-TOF AS-MS – a Viable Alternative for LC-MS-based Workflows? (PL06) |
Dr Roman SIMON
(BOEHRINGER INGELHEIM PHARMA, Biberach/Riß, Germany) |
| |
|
| 18:00 | Closing remarks & end of the conference
|
|
|
|
|
